A Phase Ib trial of MVA-EBNA1/LMP2 vaccine in nasopharyngeal carcinoma

• Research type

  Research Study

• Full title

  A Cancer Research UK Phase Ib trial to determine the safety, immunogenicity and tolerability of extended schedule vaccination with MVA-EBNA1/LMP2 in patients with Epstein Barr Virus (EBV) positive nasopharyngeal carcinoma.

• IRAS ID

  100221

• Contact name

  Neil Steven

• Contact email

  n.m.steven@bham.ac.uk

• Eudract number

  2012-002625-30

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  12/SC/0639

• Date of REC Opinion

  7 Jan 2013

• REC opinion

  Further Information Favourable Opinion